Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pediatrics, Perinatology and Child Health
Reference45 articles.
1. Dobroszycki J, Abadi J, Wiznia AA, et al. Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients. Adolesc Health Med Ther. 2011;2:85–93.
2. European Medicines Agency. Prezista (darunavir): EU summary of product characteristics. 2014. http://www.ema.europa.eu . Accessed 30 July 2015.
3. Janssen Pharmaceuticals Inc. Prezista (darunavir): US prescribing information. 2015. http://www.prezista.com . Accessed 30 July 2015.
4. Deeks ED. Darunavir: a review of its use in the management of HIV-1 infection. Drugs. 2014;74(1):99–125.
5. Flynn P, Komar S, Blanche S, et al. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naive, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE). Pediatr Infect Dis J. 2014;33(9):940–5.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献